Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

109.41USD
15 Dec 2017
Change (% chg)

$1.17 (+1.08%)
Prev Close
$108.24
Open
$109.28
Day's High
$109.64
Day's Low
$107.69
Volume
6,516,647
Avg. Vol
2,206,007
52-wk High
$147.13
52-wk Low
$94.56

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

US STOCKS-Wall St ends higher with help from tech, energy

* Cryptocurrency related stocks bounce after bitcoin futures debut

11 Dec 2017

CORRECTED-US STOCKS-Wall St rises with help from technology, energy sectors

* Cryptocurrency related stocks bounce after bitcoin futures debut

11 Dec 2017

BRIEF-Celgene Reports Long-Term Efficacy Data From Phase III Geparsepto Study

* LONG-TERM EFFICACY DATA FROM THE PHASE III GEPARSEPTO STUDY IN HIGH RISK EARLY BREAST CANCER PATIENTS TREATED WITH ABRAXANE VS. SOLVENT-BASED PACLITAXEL TO BE REPORTED

07 Dec 2017

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma

16 Nov 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

14 Nov 2017

BRIEF-Celgene prices $3 billion of senior unsecured notes

* Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

01 Nov 2017

BRIEF-Celgene announces offering of senior unsecured notes

* Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​ Source text for Eikon: Further company coverage:

31 Oct 2017

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

30 Oct 2017

BRIEF-Celgene Corp updates on court order at request of Canadian Competition Bureau - SEC filing

* Celgene Corp says ‍​in Aug, co received an order issued by the Federal Court in Ottawa, Ontario, Canada at request of Canadian Competition Bureau

26 Oct 2017

Celgene cuts 2020 outlook, Otezla sales disappoint; shares plunge

Celgene Corp on Thursday reported third-quarter sales of its key psoriasis drug Otezla that badly missed expectations and significantly scaled down its 2020 targets for product sales and earnings, sending its shares tumbling 18 percent.

26 Oct 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,294 +73.00
Eisai Co., Ltd (4523.T) ¥6,967 +72.00
Johnson & Johnson (JNJ.N) $142.46 +0.81
Novartis AG (NOVN.S) CHF83.80 -0.05
Pfizer Inc. (PFE.N) $37.20 +0.74
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Sanofi SA (SASY.PA) €73.55 --
AstraZeneca plc (AZN.L) 4,881.00 -3.50

Earnings vs. Estimates